- Can Murdoch Help Bing Challenge Google and Shift the Content Equation?
- HP's Mark Hurd
- HP Comes in As Expected; Is It Time to Buy?
- 9 Stocks That Play Rising Water Costs: Strategists
- Weis' Deal Likely Won't Change Big Money Contracts
- Gold Prices Can Double in 3 Years: Portfolio Manager
- Nov. 23: Unusual Volume Leaders
- Help Wanted—Please Run $4 Billion University
- Apple Comes to AT&T's Rescue
- Strong Banks, Weak Credit: Treasury Rethinks TARP
- How Many US Consumers Will Shop this Weekend?
- Tuesday's Heavy Dose of Data to Dictate 'Risk' Behavior
- GE Capital Losses May See Dramatic Fall: JP Morgan
- Obama says Boosting US Jobs is Top Priority
- World's Largest Share Issue Priced at Deep Discount
- Hormel Profit Jumps Despite Declining Sales
- Heinz Profit Falls, Raises Full-Year View
- Playboy to Outsource Most Magazine Operations: Report
MOST SHARED
- The 'Real' Jobless Rate: 17.5% Of Workers Are Unemployed
- Why Amazon Rules Retail
- Gold Will Collapse Like Oil Did in 2008: Charts
- China Eastern to Complete Shanghai Air Buy by End '09
- Wave of Debt Payments Facing US Government
- JAL Slides to Record Low on Bankruptcy Jitters
- Prepare For Large Decline In Stocks, Next Year?
- Paul: Audit the Fed
- Nielsen Ratings Coming to Video Games
- The Social Media Gaming Threat
Text Size 
Big pharma company Eli Lilly is coming under fire. CNBC's Pharmaceuticals Reporter Mike Huckman had the late breaking details on this morning’s “Squawk Box.” Huckman reported that
Eli Lilly [LLY
Loading...
()
] said sales of its top selling drug Zyprexa would be “stable” next year (the drug is used for schizophrenia and bipolar disorder).
But this morning--investors are skeptical about that forecast in the wake of back to back front page stories in the New York Times.
The Times reports that some patients have put on more than a hundred pounds from use of the drug. A plaintiffs' lawyer gave the times internal Lilly documents and emails suggesting the company tried to downplay those side effects.
Today the Times reports on marketing documents that indicate Lilly pushed use of the drug on elderly people with dementia--but was unapproved to do so.
Over the past few years--use of Zyprexa stopped growing as fast as it had been--because of lingering concerns over side effects like weight gain and diabetes.
Lilly says in a press release the emails and documents have been taken out of context..."these leaked documents do not accurately portray Lilly's conduct."
The threat to the Zyprexa franchise is pressuring Lilly shares ahead of the open this morning.
Analysts estimate Zyprexa is responsible for 1/3 to ½ of Lilly's profits.
Separately, Lilly is raising its bid for Icos [ICOS
Loading...
()
], set for a shareholder vote tomorrow, by two bucks to 34 dollars a share.
Less than two weeks ago Lilly CEO Sydney Taurel told Huckman he wasn't budging on the Icos price - that he considered it a full and fair offer.
- A diet high in fat and sugar might actually be good for your portfolio.
- Warren Buffett and Bill Gates discuss the economy and other subjects with CNBC's Becky Quick.
- From the AIG&T to the Merrill Lychee, Jane Wells lists this year's fashionable holiday cocktails.
- One shopper explains why – aside from the prices – he gets up at 3am on the day after Thanksgiving to go shopping every year.
- Congressman Ron Paul explains to Squawk Box why he’s pushing legislation to audit the Federal Reserve.
- …you'll want to be prepared. Tips for getting the most out of the post-Thanksgiving shopping frenzy.
Data is a real-time snapshot *Data is delayed at least 15 minutes